1014 related articles for article (PubMed ID: 29217664)
1. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.
Porta-Sánchez A; Gilbert C; Spears D; Amir E; Chan J; Nanthakumar K; Thavendiranathan P
J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29217664
[TBL] [Abstract][Full Text] [Related]
2. Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors.
Abu Rmilah AA; Lin G; Begna KH; Friedman PA; Herrmann J
Int J Cancer; 2020 Dec; 147(11):3160-3167. PubMed ID: 32449208
[TBL] [Abstract][Full Text] [Related]
3. Drug-induced QT Interval Prolongation in the Intensive Care Unit.
Etchegoyen CV; Keller GA; Mrad S; Cheng S; Di Girolamo G
Curr Clin Pharmacol; 2017; 12(4):210-222. PubMed ID: 29473523
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
Haddad PM; Anderson IM
Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926
[TBL] [Abstract][Full Text] [Related]
5. Medical toxicologists' practice patterns regarding drug-induced QT prolongation in overdose patients: a survey in the United States of America, Europe, and Asia Pacific region.
Othong R; Devlin JJ; Kazzi ZN
Clin Toxicol (Phila); 2015 May; 53(4):204-9. PubMed ID: 25706450
[TBL] [Abstract][Full Text] [Related]
6. Incidences, risk factors, and clinical correlates of severe QT prolongation after the use of quetiapine or haloperidol.
Wang CL; Wu VC; Lee CH; Wu CL; Chen HM; Huang YT; Chang SH
Heart Rhythm; 2024 Mar; 21(3):321-328. PubMed ID: 38231170
[TBL] [Abstract][Full Text] [Related]
7. Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium.
Vandael E; Vandenberk B; Vandenberghe J; Spriet I; Willems R; Foulon V
Int J Clin Pharm; 2016 Apr; 38(2):310-20. PubMed ID: 26749342
[TBL] [Abstract][Full Text] [Related]
8. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
[TBL] [Abstract][Full Text] [Related]
9. QT prolongation and safety in the Indian population.
Dabhi J; Mehta A
Curr Drug Saf; 2007 Sep; 2(3):200-3. PubMed ID: 18690968
[TBL] [Abstract][Full Text] [Related]
10. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
[TBL] [Abstract][Full Text] [Related]
11. Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk: A Pilot Study.
Strauss DG; Vicente J; Johannesen L; Blinova K; Mason JW; Weeke P; Behr ER; Roden DM; Woosley R; Kosova G; Rosenberg MA; Newton-Cheh C
Circulation; 2017 Apr; 135(14):1300-1310. PubMed ID: 28213480
[TBL] [Abstract][Full Text] [Related]
12. The QT interval.
Bednar MM; Harrigan EP; Anziano RJ; Camm AJ; Ruskin JN
Prog Cardiovasc Dis; 2001; 43(5 Suppl 1):1-45. PubMed ID: 11269621
[TBL] [Abstract][Full Text] [Related]
13. Postoperative QT interval prolongation in patients undergoing noncardiac surgery under general anesthesia.
Nagele P; Pal S; Brown F; Blood J; Miller JP; Johnston J
Anesthesiology; 2012 Aug; 117(2):321-8. PubMed ID: 22692379
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for QTc-prolongation: systematic review of the evidence.
Vandael E; Vandenberk B; Vandenberghe J; Willems R; Foulon V
Int J Clin Pharm; 2017 Feb; 39(1):16-25. PubMed ID: 28012118
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms and risks of electrocardiographic QT interval prolongation when using antipsychotic drugs.
Vieweg WV
J Clin Psychiatry; 2002; 63 Suppl 9():18-24. PubMed ID: 12088172
[TBL] [Abstract][Full Text] [Related]
16. Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration.
Kao DP; Haigney MC; Mehler PS; Krantz MJ
Addiction; 2015 Sep; 110(9):1468-75. PubMed ID: 26075588
[TBL] [Abstract][Full Text] [Related]
17. QT Prolongation and Oncology Drug Development.
Fradley MG; Moslehi J
Card Electrophysiol Clin; 2015 Jun; 7(2):341-55. PubMed ID: 26002398
[TBL] [Abstract][Full Text] [Related]
18. Prolonged QT interval in neonates: benign, transient, or prolonged risk of sudden death.
Villain E; Levy M; Kachaner J; Garson A
Am Heart J; 1992 Jul; 124(1):194-7. PubMed ID: 1352080
[TBL] [Abstract][Full Text] [Related]
19. Drug induced shortening of the QT/QTc interval: an emerging safety issue warranting further modelling and evaluation in drug research and development?
Holbrook M; Malik M; Shah RR; Valentin JP
J Pharmacol Toxicol Methods; 2009; 59(1):21-8. PubMed ID: 18834945
[TBL] [Abstract][Full Text] [Related]
20. The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach.
Polcwiartek C; Sneider B; Graff C; Taylor D; Meyer J; Kanters JK; Nielsen J
Psychopharmacology (Berl); 2015 Sep; 232(18):3297-308. PubMed ID: 26231497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
